Home › NDC Lookup › RxCUI directory › RxCUI 314184

Paromomycin 250 MG Oral Capsule — RxCUI 314184

RxNorm drug concept · Semantic clinical drug
RxCUI 314184 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 1 package NDC Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI314184
Official nameParomomycin 250 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asparomomycin (as paromomycin sulfate) 250 MG Oral Capsule; paromomycin sulfate 250 MG Oral Capsule
FDA products mapped1
Package NDCs mapped1
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

🕸️ Concept Web — How Paromomycin 250 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Paromomycin 250 MG Oral Capsule RxCUI 314184

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Paromomycin 7934
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Humatin 227565
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Paromomycin Oral Capsule 373244
    • Paromomycin Oral Product 1164134
    • Paromomycin Pill 1164135
    • Paromomycin Oral Capsule [Humatin] 366200
    • Humatin Oral Product 1171303
    • Humatin Pill 1171304
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Paromomycin 250 MG SCDC · 328487
  • Paromomycin Oral Capsule SCDF · 373244
  • Paromomycin Oral Product SCDG · 1164134
  • Paromomycin Pill SCDG · 1164135

Brand-Name Concepts

  • Paromomycin 250 MG Oral Capsule [Humatin] SBD · 207347
  • Paromomycin 250 MG [Humatin] SBDC · 568121
  • Paromomycin Oral Capsule [Humatin] SBDF · 366200
  • Humatin Oral Product SBDG · 1171303
  • Humatin Pill SBDG · 1171304
  • Humatin BN · 227565

📦 FDA Products & Package NDCs

1 product · 1 package NDC
1 package NDC map to RxCUI 314184 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
80725-0250-01 100 CAPSULE in 1 BOTTLE (80725-250-01) Humatin Waylis Therapeutics LLC 2021-04-08
Observed labelers: Waylis Therapeutics LLC (1) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.